Angion Biomedica Corp.
News
Angion Biomedica announces 1-for-10 reverse stock split
Seeking Alpha - Healthcare Angion Biomedia (ANGN) has announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10\n more…
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
Globe Newswire NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse ...\n more…
Valeo Financial Advisors LLC Reduces Holdings in Angion Biomedica Corp. (NASDAQ:ANGN)
Zolmax Valeo Financial Advisors LLC trimmed its position in shares of Angion Biomedica Corp. (NASDAQ:ANGN Get Rating) by 42.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,951 shares of the companys stock after selling 26,708 ...\n more…
Angion Biomedica First Quarter 2023 Earnings: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)
Simply Wall St Net loss: US$4.54m (loss narrowed by 68% from 1Q 2022). US$0.15 loss per share (improved from US$0.47 loss in 1Q 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is expected to decline by 122% p.a.\n more…
Angion Biomedica Corp. (NASDAQ:ANGN) Short Interest Update
Ticker Report Angion Biomedica Corp. (NASDAQ:ANGN Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 81,200 shares, an increase of 12.9% from the March 15th total of 71,900 shares. Currently, 0.4% of the company&#...\n more…
Head-To-Head Survey: Angion Biomedica (NASDAQ:ANGN) & MannKind (NASDAQ:MNKD)
Zolmax Angion Biomedica (NASDAQ:ANGN Get Rating) and MannKind (NASDAQ:MNKD Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation...\n more…